Newtyn Management LLC Reduces Stake in Teleflex Incorporated $TFX

Newtyn Management LLC decreased its holdings in shares of Teleflex Incorporated (NYSE:TFX) by 23.7% during the second quarter, according to its most recent filing with the SEC. The firm owned 305,000 shares of the medical technology company’s stock after selling 95,000 shares during the period. Teleflex accounts for about 4.9% of Newtyn Management LLC’s portfolio, making the stock its 7th largest position. Newtyn Management LLC owned 0.72% of Teleflex worth $38,662,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the business. Kelleher Financial Advisors bought a new position in shares of Teleflex during the second quarter valued at approximately $25,000. Banque Cantonale Vaudoise raised its stake in Teleflex by 82.5% in the fourth quarter. Banque Cantonale Vaudoise now owns 250 shares of the medical technology company’s stock worth $31,000 after buying an additional 113 shares in the last quarter. UMB Bank n.a. lifted its holdings in Teleflex by 57.1% during the fourth quarter. UMB Bank n.a. now owns 311 shares of the medical technology company’s stock worth $38,000 after buying an additional 113 shares during the period. Allworth Financial LP bought a new stake in Teleflex during the 2nd quarter valued at $44,000. Finally, Kestra Advisory Services LLC bought a new stake in Teleflex during the 4th quarter valued at $45,000. Institutional investors own 95.62% of the company’s stock.

Teleflex Stock Performance

Shares of TFX opened at $139.81 on Monday. Teleflex Incorporated has a 12 month low of $100.18 and a 12 month high of $145.00. The stock has a fifty day moving average price of $133.86 and a 200-day moving average price of $126.05. The company has a current ratio of 2.60, a quick ratio of 2.12 and a debt-to-equity ratio of 0.94. The firm has a market cap of $5.92 billion, a PE ratio of -6.00, a P/E/G ratio of 0.93 and a beta of 0.81.

Teleflex (NYSE:TFX) last posted its quarterly earnings data on Thursday, August 6th. The medical technology company reported $1.76 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.48. Teleflex had a positive return on equity of 11.93% and a negative net margin of 39.67%.The firm had revenue of $570.33 million during the quarter, compared to analysts’ expectations of $559.59 million. During the same quarter last year, the firm earned $3.73 EPS. The business’s quarterly revenue was up 28.9% on a year-over-year basis. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. Equities research analysts predict that Teleflex Incorporated will post 7.26 earnings per share for the current fiscal year.

Teleflex Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Friday, August 14th will be issued a $0.34 dividend. This represents a $1.36 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Friday, August 14th. Teleflex’s dividend payout ratio (DPR) is currently -5.84%.

Analysts Set New Price Targets

Several research analysts have recently commented on TFX shares. UBS Group boosted their price target on Teleflex from $145.00 to $158.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 11th. Needham & Company LLC raised their price objective on Teleflex from $159.00 to $170.00 and gave the company a “buy” rating in a research report on Tuesday, August 25th. Royal Bank Of Canada upgraded Teleflex from a “sector perform” rating to an “outperform” rating and lifted their target price for the company from $135.00 to $155.00 in a research note on Friday, May 8th. Piper Sandler reiterated an “overweight” rating and issued a $169.00 target price (up from $160.00) on shares of Teleflex in a report on Friday, August 7th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Teleflex in a research report on Wednesday, June 24th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $152.90.

Teleflex Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.